Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ANA380: Final Phase I/II data

In a double-blind, placebo-controlled, dose-escalation, Chinese and Korean Phase

Read the full 98 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE